Prof. Dr. Meral Beksaç

Frontline therapy for multiple myeloma (MM) in real-world clinical practice: Results from the third interim analysis of the multinational, non-interventional, observational EMMOS study

Clinical Lymphoma Myeloma & Leukemia, 2015

DOI 10.1016/j.clml.2015.07.321 2 atıf (OpenAlex) Kaynak: OpenAlex

Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice

Blood, 2015

DOI 10.1182/blood.v126.23.3034.3034 1 atıf (OpenAlex) Kaynak: OpenAlex

Comparative Proteomic Analysis of Bone Marrow Plasma Cells By Using Mass Spectrometry Based Bottom up Proteomic Strategies

Blood, 2015

DOI 10.1182/blood.v126.23.5334.5334 1 atıf (OpenAlex) Kaynak: OpenAlex

Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment

Blood, 2015

DOI 10.1182/blood.v126.23.4230.4230 1 atıf (OpenAlex) Kaynak: OpenAlex

Frontline induction therapy for multiple myeloma (MM) in real-world clinical practice: Third interim analysis of the multinational, observational EMMOS study (NCT01241396)

University of Southern Denmark Research Portal (University of Southern Denmark), 2015

1 atıf (OpenAlex) Kaynak: OpenAlex

Central Nervous System Involvement by Multiple Myeloma: a Multi-Institutional Retrospective Study of 172 Patients

Clinical Lymphoma Myeloma & Leukemia, 2015

DOI 10.1016/j.clml.2015.07.322 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Expression and in Vitro Binding of Protease Activated Receptor1 (PAR1) with Novel Anti-PAR1 Molecules: Data on Fresh Myeloma Marrow Plasma Cells and Human Myeloma Cell Lines

Blood, 2015

DOI 10.1182/blood.v126.23.4440.4440 1 atıf (OpenAlex) Kaynak: OpenAlex

Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.

Journal of Clinical Oncology, 2015

DOI 10.1200/jco.2015.33.15_suppl.8526 6 atıf (OpenAlex) Kaynak: OpenAlex

Frequency Of Protease Activated Receptor1 (PAR1) Expression And The In Vitro Effects Of XT5 And XT2B, Two Novel PAR1 Binding Molecules, On Primary And Bortezomib Refractory Myeloma Cell Lines

Clinical Lymphoma Myeloma & Leukemia, 2015

DOI 10.1016/j.clml.2015.07.501 Kaynak: OpenAlex

Autologous Stem Cell Transplantation and Primary Systemic Light Chain (AL) Amyloidosis

Clinical Lymphoma Myeloma & Leukemia, 2015

DOI 10.1016/j.clml.2015.07.396 Kaynak: OpenAlex

The Effect of Pre-Transplant Psychological Well-Being on Hematological Reconstitution Following Autologous Stem Cell Transplantation in Multiple Myeloma Patients

Blood, 2015

DOI 10.1182/blood.v126.23.5619.5619 Kaynak: OpenAlex

Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation

Blood, 2015

DOI 10.1182/blood.v126.23.5456.5456 Kaynak: OpenAlex

Ankara Üniversitesi Kordon Kanı ve Kök Hücre Bankası: hizmet ve alt yapı devamlılığı projesi

2015

Kaynak: OpenAlex

Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients.

Journal of Clinical Oncology, 2015

DOI 10.1200/jco.2015.33.15_suppl.e18088 Kaynak: OpenAlex

Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study

American Journal of Hematology, 2014

DOI 10.1002/ajh.23641 PMID 24273190 19 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

European myeloma network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma

Haematologica, 2014

DOI 10.3324/haematol.2013.099358 PMID 24497560 144 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

High-Dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: Results of the EORTC-GIMEMA AML-12 trial

Journal of Clinical Oncology, 2014

DOI 10.1200/jco.2013.51.8571 PMID 24297940 136 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

The Lancet Oncology, 2014

DOI 10.1016/s1470-2045(14)70442-5 PMID 25439696 3.321 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: A multicentre, randomised, double-blind phase 3 trial

The Lancet Oncology, 2014

DOI 10.1016/s1470-2045(14)70440-1 PMID 25242045 629 atıf (Europe PMC) Kaynak: ORCID

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

Haematologica, 2014

DOI 10.3324/haematol.2014.112037 PMID 25261096 26 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Unrelated adult stem cell donor medical suitability: Recommendations from the world marrow donor association clinical working group committee

Bone Marrow Transplantation, 2014

DOI 10.1038/bmt.2014.67 PMID 24710563 29 atıf (Europe PMC) Kaynak: ORCID

Preface

Methods in Molecular Biology, 2014

Kaynak: ORCID

Impact of PET-CT Response on Survival Parameters Following Autologous Stem Cell Transplantation Among Patients with Multiple Myeloma: Comparison of Two Cut-Off Values

Blood, 2014

DOI 10.1182/blood.v124.21.3983.3983 19 atıf (OpenAlex) Kaynak: OpenAlex

Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

Blood, 2014

DOI 10.1182/blood.v124.21.2120.2120 6 atıf (OpenAlex) Kaynak: OpenAlex

Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study

Blood, 2014

DOI 10.1182/blood.v124.21.4742.4742 5 atıf (OpenAlex) Kaynak: OpenAlex

Bone Marrow and Stem Cell Transplantation

Methods in molecular biology, 2014

DOI 10.1007/978-1-4614-9437-9 10 atıf (OpenAlex) Kaynak: OpenAlex

Management of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation

Transplantation and Cellular Therapy, 2014

DOI 10.1016/j.bbmt.2013.12.321 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Treatment Approaches in Acute Leukemia Patients Relapsing Following Allogeneic Hematopoietic Stem Cell Transplantation

Blood, 2014

DOI 10.1182/blood.v124.21.5891.5891 Kaynak: OpenAlex

Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?

Blood, 2014

DOI 10.1182/blood.v124.21.5555.5555 Kaynak: OpenAlex

Do FMS-like Tyrosine Kinase 3 and Nucleophospmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?

Blood, 2014

DOI 10.1182/blood.v124.21.5328.5328 Kaynak: OpenAlex

Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt’s Lymphoma: A Single Center Experience

Blood, 2014

DOI 10.1182/blood.v124.21.5448.5448 Kaynak: OpenAlex

Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients

Blood, 2014

DOI 10.1182/blood.v124.21.5887.5887 Kaynak: OpenAlex

Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center

Blood, 2014

DOI 10.1182/blood.v124.21.5150.5150 Kaynak: OpenAlex

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: Long-term results of the EBMT-NMAM2000 study

Blood, 2013

DOI 10.1182/blood-2012-11-469452 PMID 23482933 141 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease

Wiener Klinische Wochenschrift, 2013

DOI 10.1007/s00508-013-0385-4 PMID 23832237 3 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

Haematologica, 2013

DOI 10.3324/haematol.2013.084376 PMID 23716559 30 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Safety of thalidomide in newly diagnosed elderly myeloma patients: A meta-analysis of data from individual patients in six randomized trials

Haematologica, 2013

DOI 10.3324/haematol.2012.067058 PMID 22875621 60 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Comparison Of Flow Cytometric and Clinical Findings In Patients With Paroxysmal Nocturnal Hemoglobinuria

Blood, 2013

DOI 10.1182/blood.v122.21.4877.4877 1 atıf (OpenAlex) Kaynak: OpenAlex

Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)

Blood, 2013

DOI 10.1182/blood.v122.21.3177.3177 2 atıf (OpenAlex) Kaynak: OpenAlex

Induction Therapy in Multiple Myeloma

InTech eBooks, 2013

DOI 10.5772/55151 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Preliminary Results Of A Mass Spectrometry Based Bottom Up Proteomic Approach On Bone Marrow Plasma Cells From Patients With Multiple Myeloma (MM)

Blood, 2013

DOI 10.1182/blood.v122.21.1887.1887 1 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

Hepa systems in hematology clinic to ameliorate the increased fungal infection risk owing to environmental changing.

Journal of Clinical Oncology, 2013

DOI 10.1200/jco.2013.31.15_suppl.e18009 Kaynak: OpenAlex

Comparison of allogeneic stem cell transplantations in chronic myeloid leukemia before and after the era of tyrosine kinase inhibitors.

Journal of Clinical Oncology, 2013

DOI 10.1200/jco.2013.31.15_suppl.7038 Kaynak: OpenAlex

Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells

Stem Cell Reviews and Reports, 2012

DOI 10.1007/s12015-012-9376-5 PMID 22552878 24 atıf (Europe PMC) Kaynak: OpenAlex

A FOURIER TRANSFORM INFRARED SPECTROSCOPIC INVESTIGATIONS ON THE MOLECULAR PROFILING OF MULTIPLE MYELOMA

Haematologica, 2012

Kaynak: ORCID

A Phase 2, Multicenter, Nonrandomized, Open-Label Study of Dovitinib (TKI258) in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation

Blood, 2012

DOI 10.1182/blood.v120.21.4055.4055 4 atıf (OpenAlex) Kaynak: ORCID

Case-matched comparison with standard versus reduced intensity conditioning regimen in chronic myeloid leukemia patients

Annals of Hematology, 2012

DOI 10.1007/s00277-011-1349-2 PMID 21971669 11 atıf (Europe PMC) Kaynak: ORCID

Continuous lenalidomide treatment for newly diagnosed multiple myeloma

New England Journal of Medicine, 2012

DOI 10.1056/nejmoa1112704 PMID 22571200 563 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

Flow cytometric evaluation of cell cycle regulators (cyclins and cyclin-dependent kinase inhibitors) expressed on bone marrow cells in patients with chronic myeloid leukemia and multiple myeloma,Kronik miyelositer lösemi ve multipl miyelom olgularındaki kemik İliǧi kaynaklı hücrelerde, hücre siklusu düzenleyicilerinin (siklinler ve siklin baǧımlı kinaz İnhibitörleri) akım sitometrik olarak deǧerlendirilmesi

Turkish Journal of Hematology, 2012

DOI 10.5505/tjh.2012.33602 PMID 24744619 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

IMWG consensus on maintenance therapy in multiple myeloma

Blood, 2012

DOI 10.1182/blood-2011-11-374249 PMID 22271445 130 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID